The Australian government founds the Commonwealth Serum Laboratories in Melbourne. CSL is later privatized and listed (1994). Plasma is still the larger P&L; Seqirus is the vaccine arm.

CSL completes the purchase of Novartis's influenza vaccines business and launches the Seqirus brand. Flucelvax (cell) and Fluad (adjuvanted) sit here.

Seqirus FY Jun 2025: $2.166B total, Fluad $901M, Flucelvax $474M. Fiscal year is June, not calendar. Label the offset when comparing to Sanofi flu.